



UNIVERSITY OF
EASTERN FINLAND

PET basics - and imaging at Kuopio-Biomedical Imaging Unit (Kuopio-BIU)

FIN3R symposium 6.11.2023

Kimmo Jokivarsi

Staff Scientist

Kuopio-BIU, A.I.Virtanen institute


UEF, Kuopio campus

UEF// University of Eastern Finland



FINNISH
BIOMEDICAL
IMAGING





**We are in the middle
of knowhere. UEF.**



Kuopio Biomedical Imaging Unit (BIU)

National pre-clinical MRI center
Part of Finnish Biomedical Imaging-node in EuroBioImaging

Access to academic and commercial researchers

Ex Vivo



0.7 T (29.8 MHz) 3 T 7 T 9.4 T 11.7 T (500MHz)

In Vivo



Simultaneous PET/MRI

Nuclear Imaging (BIU+KUH)



PET



PET tracers



uCT

MRI community of ~35 researchers

Faculty of Health

Prof. Olli Gröhn
Prof. Jussi Tohka
Res.Dir. Alejandra Sierra Lopez
Res.Dir. Mikko Kettunen
Res. Elias Ylä-Herttuala (KUH)

Faculty of Natural Sciences

Res.Dir. Mikko Nissi
Prof. Ville Kolehmainen

Functional MRI
Advanced data-analysis
Microstructural MRI
Metabolic MRI
Cardiac MRI


Cartilage MRI
Advanced data-analysis



Kuopio Biomedical Imaging Unit (BIU)

National pre-clinical MRI center
Part of Finnish Biomedical Imaging-node in EuroBioImaging

} Access to academic and
commercial researchers



➡ Structure – Function – Metabolism – Clinical translation




Kuopio Biomedical Imaging Unit (BIU)

National pre-clinical MRI center
Part of Finnish Biomedical Imaging-node in EuroBioImaging


Access to academic and commercial researchers

Recent projects


MRI of rat eye




Body fat distribution




Mouse cardiac MRI




Mn enhanced MRI




Novel MR contrast agents




Brain metabolism in trauma



MRI of pine seed





MRI of paper



Microstructural MRI (Sierra, Multiscale Imaging Group)


Water diffusion

MR voxel $\sim (50\mu\text{m})^3$




Microscopy


Light



Confocal




Electron



Diffusion MRI is sensitive to tissue microstructure

Correlation with microscopy


Segmentation and modeling



Abdollahzadeh et al. (2021) *Commun Biol.*

Silent Functional MRI (Gröhn)

Functional networks in awake animals



1. Technical development
2. Epilepsy
3. De/Remyelination

Paasonen et al. (2022) *Neuroimage*

Metabolic MRI (Kettunen)

Hyperpolarisation allows **>10,000-fold transient increase of e.g. ^{13}C signal**

⇒ Real-time metabolic spectroscopy and spectroscopic imaging



Sample pre-polarised,
MRI can be performed
even at low magnetic field



~80mM
100-700k ppm
polarisation




Cells,
Organoids




Pre-clinical
imaging



Clinical
translation




Gene therapy response




Nivajärvi/Olsson et al. (2020) *NMR Biomed*

Radionuclide Imaging


Brain inflammation




Hypometabolism in TBI



Nanomedicine



Cardiac metabolism




PET tracers (KUH)

^{18}F and ^{11}C -labelled tracers
 ^{18}F -FDG, ^{18}F -FEPPA, ^{18}F -Fallypride, ^{18}F -PE2i, ^{18}F -FPEB ...
 ^{68}Ga and ^{89}Zr -labelled particles



Simultaneous
whole-body
PET/MRI


PET




Positron Emission Tomography




Bits of History of PET...




Brownell, G.L., Sweet, W.H. "Localization of brain tumors with positron emitters", Nucleonics 1953, 11:40-45.





1953 - First clinical positron imaging device designed for brain imaging




1962 - First Multiple Detector Positron Imaging Device



First positron track observed by Carl Anderson (1932)



1968 - PC-I The First Tomographic (Positron) Imaging Device and the First Computed Tomographic Imaging Device



1975 - PETT prototype



PET

Some bits of the basics...



Nuclear imaging & tracers


- Nuclear imaging uses radioactive tracers (radiopharmaceuticals) to e.g. assess bodily functions and to diagnose disease
- Molecular imaging probe (=tracer)
 - Chemical **compound with specificity** for molecular targets
 - A component that provides **signal** to be detected
 - External detectors capture and form images from **radiation** emitted by tracers
- Tracer applied in trace (i.e. minimal) amounts that can be detected
 - > has no pharmacologic effect in vivo
- Functional imaging
 - Increased physiological function -> increased concentration of tracer -> hot-spot
 - Some disease processes result in exclusion of a tracer -> cold-spot
- High sensitivity (10^{-11} – 10^{-12} mol/L)
 - PET 50-100 times more sensitive than SPECT (10^7 times more vs MRI)



Positron Emission for Tomography...

Fluorine-18 (^{18}F)

- Produced with cyclotron ($[^{18}\text{O}]\text{H}_2\text{O}$)
- The most often used **positron emitter**
- Small (radioactive) atom (isotope)
 - > when added to a molecule does not deform it "beyond recognition"
- Half-life 109min
 - > i.e. 50% of activity gone in ~2h
 - > long enough for chemistry (labelling) and transportation
- Low radiation burden to patient



Fluorine-18 decay into Oxygen-18

Positron (β^+) emission (and a neutrino)


→ Collision with electron (e^-)

→ Annihilation

→ 2 γ 's exiting opposite directions

→ 2 "simultaneous" detections (true event)


Collecting data of $\sim 10^9$ events





From coincidence to image


PET data collection



Histogramming
(cleanup, windowing)



Image reconstruction
(e.g. back projection)





<https://humanhealth.iaea.org/HHW/m/MedicalPhysics/NuclearMedicine/ImageAnalysis/3Dimagereconstruction/index.html>



Preclinical PET (Glucose metabolism example)

^{18}F -FDG:
Glucoseanalogue





Preclinical PET + CT + MRI




CT




MRI



ROI data



Time-Activity Curve



Tomographic Image (slice)



Where to use PET? E.g. ...

- Molecule biodistribution studies
 - Does the molecule reach target tissue?
 - Does it accumulate in non-target sites (potential toxicity)?
- Dose selection (dose–target occupancy measurements)
- Identify or validate new imaging biomarkers
- Search for surrogate markers of e.g. treatment response
- Compare current medicine vs new compounds
- Earlier detection of disease or associated pathology (before anatomical changes)
- Diagnosis of pre- or minimally symptomatic disease
- Patient grouping (e.g. disease sub-phenotype or early treatment response)



Cancer therapy monitoring:

The diagram illustrates various cancer-related processes and their associated imaging techniques:

- Metastasis**: Imaging options include PET (^{64}Cu)AMD3100 and MR: Ferumoxtran-10.
- Angiogenesis**: Imaging options include PET (^{18}F)RGD peptides, VEGF and receptors, [^{15}O]H₂O, and MR: RGD-labeled paramagnetic particles, DCE.
- Stem cells**: Imaging options include PET (^{18}F)FDG and MR: paramagnetic particles.
- Proliferation**: Imaging options include PET (^{18}F)FLT.
- Cellular metabolism**: Imaging options include Glucose metabolism: PET (^{18}F)FDG, Amino acid metabolism: PET (^{11}C)Methionine, Hypoxia: PET (^{18}F)FMISO, and MR: BOLD.
- Evasion of apoptosis**: Imaging options include MR: DWI, AnnexinV-labeled nanoparticles, and PET: [^{67}Ga] [^{67}Ga] [^{67}Ga].

Associated research studies and images are provided for each process:

- Stormezand et al. 2018**: Image showing metastasis.
- Munck af Rosenschold et al. 2011**: Image showing cellular metabolism.
- Takenaka et al. 2015**: Image showing angiogenesis.
- Quartuccio & Asselin 2017**: Image showing stem cells.
- Hong et al. 2008**: Image showing proliferation.
- Nimmagadda et al. 2010**: Image showing proliferation.
- Jensen et al. 2013**: Image showing proliferation.
- Visith Keu et al. 2017**: Image showing stem cells.

Bg image from: Sauter et al. J Mol Med 2019

Cardiac Molecular Imaging Targets

Stem Cell Engraftment

Presynaptic Sympathetic Innervation

Postsynaptic Adrenergic Receptors

Metabolism

Renin-Angiotensin System (RAS)

Matrix-Metalloproteinase (MMP)

Integrins

Gene Expression / Reporter Gene Imaging

Membrane Integrity / Apoptosis / Cell

Extracellular Space

Plasma Membrane

Cytoplasm

Mitochondrion



Nucleus

Labels: Labeled Stem Cell, Labeled Adrenoceptor or Ligand, Labeled Catecholamine Analogue, Labeled Glucose Analogue, Labeled Fatty Acid Analogue, Labeled Acetate, Labeled ATR Ligand, ACE Inhibitor, Labeled MMP Ligand, Labeled Integrin Ligand, Vector, Reporter Gene, Reporter Gene Product, Labeled Reporter Probe, Labeled Antimyosin, Labeled Annexin.

**-> Many molecular targets
and many (potential) tracers
available for imaging**



PET quantification: Compartment model



Differential equations:

$$\frac{dC_{free}(t)}{dt} = K_1 C_{plasma}(t) - (k_2 + k_3) C_{free}(t) + k_4 C_{bound}(t)$$


$$\frac{dC_{bound}(t)}{dt} = k_3 C_{free}(t) - k_4 C_{bound}(t)$$

$$PET(t) = C_{free}(t) + C_{bound}(t) + C_{plasma}(t)$$

Microparameters:
 K_1, k_2, k_3, k_4

Derived compound
parameters:

- Robust
- Biological meaning
 - BP = Binding potential (receptor occupancy)
 - V_d = Volume of distribution (ligand distribution vs C_P)







Things affecting quantitative data & results

- Corrections for quantitative 2D- and 3D-data:


- Detector (normalization)
 - For sensitivity of each detector on the ring
- Randoms
- Scatter correction
- Attenuation correction (AC)
 - Tissue attenuation
- Dead-time correction



← Problem!

- Isotope

- ^{18}F , ^{11}C , ^{15}O , ...
- Half-life, β^+ -energy ($\rightarrow \beta^+$ range)



- Tracer (molecule)


- e.g. ^{18}F -FDG (glucose), ^{11}C -raclopride (dopamine), ^{18}F -FEPPA (inflammation)...

- Reconstruction algorithm

- FBP, MLEM, OSEM, ...
- A priori info

- Physics (resolution, uncertainty, ...)

- Non-collinearity of the photons (180 ± 0.25 degrees)
- Detector (crystal type, dimensions and location)
- Motion (of the patient; breathing, heart)
- ...






3R principle in practise

- Reduction
 - Longitudinal studies (minimally or non-invasive)
 - By keeping data (e.g. image) quality good
 - Large volume, 4D data; can be reused/revisited for other targets
- Replacing
 - Phantom studies as tech check
 - But we do *in vivo* imaging...
- Refining
 - Animal welfare in constant discussion
 - Improved living environment, animal handling, anesthesia and pain medication, aseptic operations, ...




Current and future



- Happy to add more collaboration!

Clinical tumor localization with positron imaging

(Botterell EH et al. CMAJ 1961)



~1960's



UNIVERSITY OF
EASTERN FINLAND

Thank you!


<http://www.uef.fi/kuopiobiu/>

uef.fi



Astrocytoma with PET-MRI

(Boss et al. J Nucl Med)



2010